A 2022 meta-analysis published in Cardiovascular Diabetology examining GLP-1 receptor agonist effects on lipid profiles found that semaglutide and tirzepatide produced statistically significant reductions in triglycerides across all trials examined, with the magnitude of reduction correlating with both the degree of weight loss achieved and baseline triglyceride levels, supporting the clinical rationale for GLP-1 use in patients with hypertriglyceridemia alongside obesity
now meets demand
Other causes include strict vegan diets, malabsorption disorders (coeliac disease, Crohn's disease), gastrointestinal surgery, and long-term use of medications such as metformin or proton pump inhibitors
We specialize in bioidentical hormone replacement therapy, testosterone injections, and holistic treatments designed to combat weight gain, improve libido, improve sleep and enhance overall well-being
The injection may be worth discussing with your doctor if: Your mornings are rushed, unpredictable, or include early eating or drinking
Insurance Coverage Insurance often covers GLP-1 drugs for diabetes treatment, but it is less reliable when it comes to obesity